Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai to Build New Oral Solid Dose Plant in Suzhou

publication date: Feb 25, 2015
Eisai Co. of Japan announced plans to build a second new plant in the Suzhou Industrial Park, which will make oral solid dose products. The new facility, which will replace an existing Suzhou plant, will be built next to the parenteral facility that Eisai completed in December. Because Eisai anticipates increased demand for its products in China, the new facility will expand capacity to provide stable supply of oral solid dose drugs, including Methycobal, Aricept and Pariet for the China market. More details....

Stock Symbol: (TO: 4523)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital